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ABSTRACT 
CHO cell lines capable of high-level recombinant protein product biosynthesis during fed-
batch culture are still generally obtained by intensive empirical screening of transfected cells 
rather than knowledge-guided cellular engineering. In this study, we investigate how CHO cell 
lines create and maintain cellular biosynthetic capacity during fed-batch culture to achieve the 
optimal combination of rapid exponential proliferation and extended maintenance of high cell 
biomass concentration. We perform a comparative meta-analysis of mitochondrial and 
glycolytic functions of 22 discrete parental CHO cell lineages varying in fed-batch culture 
performance to test the hypotheses that (i) “biomass-intensive” CHO cells exhibit conserved 
differences in metabolic programming and (ii) it is possible to isolate parental CHO cell lines 
with a biomass-intensive phenotype to support fed-batch bioproduction processes. We show 
that for most parental CHO cell lines, rapid proliferation and high late-stage culture 
performance are mutually exclusive objectives. However, quantitative dissection of 
mitochondrial and glycolytic functions revealed that a small proportion of clones utilize a 
conserved metabolic program that significantly enhances cellular glycolytic and mitochondrial 
oxidative capacity at the onset of late-stage culture. We reveal the central importance of 
dynamic metabolic re-programming to activate oxidative mitochondrial function as a necessary 
mechanism to support CHO cell biosynthetic performance during culture. This article is 
protected by copyright. All rights reserved 
 
Keywords: Chinese hamster ovary cells, metabolic phenotype, cell biomass, directed 
evolution, mitochondria, glycolysis. 
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INTRODUCTION 
Industrial procedures to create and isolate high-performance CHO cell lines for 
biopharmaceutical manufacturing process development are currently reliant upon high-
throughput screening technologies to identify clonal isolates with favorable cell culture process 
performance (i.e. production, stability) and recombinant product attributes. Although previous 
studies have identified alterations in CHO metabolism associated with transition through cell 
culture phases (Ahn and Antoniewicz 2011; Ahn and Antoniewicz 2013; Templeton et al. 
2013; Young 2013), we still do not generally understand how some CHO cells, and not the 
majority of others, can adapt metabolic function to achieve both rapid proliferation and 
maintenance of high viable cell biomass in vitro. 
Substantial increases in cellular biomass synthesis in vitro have been obtained over 
recent years, typically as a result of iterative empirical media, feed and process design rather 
than a priori knowledge-guided genetic engineering of cellular controls on biomass synthesis. 
Despite efforts to engineer CHO cell metabolism by a variety of means (Dorai et al. 2009; 
Wilkens and Gerdtzen 2011; Wlaschin and Hu 2007; Zhou et al. 2011), cells in chemically-
defined media generally still proliferate slowly (doubling time 20–24h) and the specific rate of 
biomass synthesis markedly declines during culture. Screening of engineered CHO cell 
populations with varying genetic/functional properties is generally the route taken to obtain 
clonal derivatives with improved bioproduction capability (Porter 2015; Prentice et al. 2007; 
Sinacore et al. 2000). Related to this, deliberate mining of the functional (phenotypic) diversity 
of host cell clones offers the opportunity to isolate efficient, but rare, clonal variants with 
enhanced biomanufacturing capabilities (Davies et al. 2012; O'Callaghan et al. 2015). 
However, to the best of our knowledge, no studies have analyzed, from a metabolic 
programming prospective, how maximal rates of CHO cell biomass synthesis are achieved by 
some clones and not others. In this study we functionally dissect the cellular bioenergetics, 
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specifically mitochondrial and glycolytic functions of 22 discrete CHO clonal lineages varying 
in the extent to which they can create and maintain cell biomass during fed-batch culture. We 
reveal that high-performance “biomass-intensive” parental CHO cells employ a rare but 
conserved metabolic phenotype characterized by an ability to switch-on oxidative metabolism 
at the onset of stationary-phase culture. We show that it is possible to obtain significantly 
improved host CHO cell phenotypes by analysis of multi-parallel subcultures, exploiting 
acquired diversity in metabolic programming. 
 
MATERIALS AND METHODS 
CHO-S cell cloning and long-term cell culture 
A donor parental CHO-S cell line (Life Technologies, Paisley, UK) was used to isolate 22 
clonally-derived cell lines using two rounds of limited dilution cloning (LDC) in 96-well plates 
as described previously (Davies et al. 2012), yielding a probability of clonality of 0.97 and a 
cloning efficiency of 1.15%. After 63 days of expansion in static culture in CD-CHO medium 
containing 8 mM L-glutamine – with a sequential scaling up from 96-well plate into a 24-well 
plate, 6-well plate, and T-75 cell culture flask, 22 clonally-derived cell lines were transferred 
into individual 125 mL Erlenmeyer suspension culture flasks, maintained at 37°C, 140 rpm 
under 5% CO2 and cultured until cell viability was recovered and maintained above 95% for 
three consecutive passages. At this point, generation number was set at zero and cells were 
sampled for cell banking. 
For extended exponential subculture up to 220 generations, clonally-derived cell lines 
were routinely maintained in TubeSpin bioreactor tubes (TPP, Trasadingen, Switzerland) at a 
working volume of 6 mL in glutamine-supplemented (8 mM) CD-CHO medium at 37°C, 140 
rpm under 5% CO2. Cells were subcultured every 3–4 days at a seeding density of 2 x 105 
viable cells mL-1. Cell density and viability were routinely measured using the Vi-CELL XR 
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(Beckman Coulter, High Wycombe, UK) and cell samples (subclones) were cryopreserved at 
approximately 80 and 200 generations. Cell specific growth rate (µ) and generation number 
(GN) were calculated as previously described (Davies et al., 2013). 
Prior to cryopreservation, cells were harvested at mid-exponential growth phase, 
centrifuged at 200×g for 5 min and resuspended in cold glutamine-supplemented CD-CHO 
medium containing 10% (v/v) DMSO at a density of 6.6×106 viable cells mL-1. Aliquots (1.5 
mL) were dispensed into cryovials (Thermo Scientific Nunc, Loughborough, UK) and placed 
immediately into a controlled-rate freezing container (Thermo Scientific Nunc). Cryovials 
were placed in a –20°C freezer for 4 h, transferred into a –80°C freezer overnight and then into 
a liquid nitrogen cryostat for long-term storage. 
 
Fed-batch culture of CHO-S subclones 
A multi-day supplementation strategy was optimized using CD-CHO EfficientFeed B (Life 
Technologies) as nutrient supplement according to the manufacturer’s instructions. The 
feeding strategy supporting the highest peak viable cell concentration (VCC) and integral of 
viable cell concentration (IVCC) performance was selected as the optimal feeding regimen. 
Optimized fed-batch culture (FBC) performance was carried out after four passages post-thaw. 
Briefly, FBCs were inoculated at 2×105 viable cells mL-1 in 125 mL Erlenmeyer shake flasks 
containing 25 mL of glutamine supplemented CD-CHO medium. The multi-day 
supplementation regime consisted in adding 10% (v/v) CD-CHO EfficientFeed B at days 3, 5, 
7 and 9. VCD, cell viability and cell diameter were assessed daily using the Vi-CELL XR. All 
cultures were maintained at 37qC, 140 rpm under 5% CO2 until cell viability dropped below 
60%. Across all cell populations analyzed, a Gaussian frequency distribution of cell 
diameter/volume was evident. Therefore, we confidently utilized mean cell volume as a reliable 
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population descriptor. The IVCC and integral of viable cell volume (IVCV) were calculated as 
follows: 
IVCC [cell h mLିଵ] = (௑భି௑బ) (௧భି௧బ)୐୬ቀ೉భ೉బቁ   (Equation 1) (Prentice et al. 2007)) 
IVCV [mmଷ h mLିଵ] = (௏భ௑భି௏బ௑బ)(௧భି௧బ)୐୬ቀ೉భ೉బቁ   (Equation 2) 
where X1 and X0 are the VCC at final and initial time points, respectively, t 1 and t0 are the time 
at final and initial time points, respectively, V1 and V0 are the mean cell volume at final and 
initial time points, respectively. 
 
Mitochondrial and glycolytic extracellular flux bioenergetics analysis 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured 
using the cell metabolic analyzer Seahorse XF24 (Seahorse Biosciences, North Billerica, MA) 
according to the manufacturer’s instructions. Briefly, 1.2×106 viable cells well-1 were plated in 
Seahorse XF24 plates previously coated with BD Cell-Tak cell and tissue adhesive (BD 
Biosciences, Oxford, UKȝJmL-1 for 20 min) and incubated at 37°C under 5% CO2 in a 
VWDWLF LQFXEDWRU IRU  PLQ &RQGLWLRQHG PHGLD ZDV UHSODFHG ZLWK  ȝ/ Rf unbuffered 
Seahorse XF media, supplemented with 2 mM L-glutamine and 16.74 mM glucose (pH 7.4) 
for the OCR analysis or with only 2 mM L-glutamine for the ECAR analysis. Plates were 
immediately incubated at 37°C in a CO2-free incubator for 30 min before being loaded onto 
the analyzer. Three real-time measurements of OCR and ECAR were directly measured (basal 
readings) and after injection of different mitochondrial inhibitors or glycolytic modulators. For 
OCR, the cells were sequentially treated with optimized concentrations of oligomycin ȝ0), 
carbonyl cyanide p-[trifluoro-methoxy]-phenyl-hydrazone (FCCP  ȝ0) and 
rotenone/antimycin A  ȝ0, while for ECAR the cells were sequentially treated with 
RSWLPL]HGFRQFHQWUDWLRQRIJOXFRVHP0ROLJRP\FLQȝ0DQG-deoxy-D-glucose 
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(100 mM). Cell seeding, oligomycin, FCCP, rotenone and antimycin A concentrations were 
optimized according to the manufacturer’s instructions. To exclude any cell volume effects 
across clonal derived cell lines, all specific metabolic rates, mitochondrial and glycolytic 
activities were corrected for cell volume using the following volume factor: 
Volume factor =
௏ౙ౛ౢౢσ ೇౙ౛ౢౢ೙೔ ೙     (Equation 3) 
where Vcell is the mean cell volume of each individual cell line in the study, n is the total number 
of cell lines in the study. 
 
Metabolite assay 
Prior to analysis, culture medium was centrifuged at 200×g for 5 min to remove cells. Glucose, 
lactate and glutamine concentrations were determined by colorimetric methods using the Cedex 
Bio (Roche Diagnostics, West Sussex, UK) according to the manufacturer’s instructions. The 
specific metabolic flux rate (qMet) was calculated as follows: 
qMet [pmol cellିଵ hିଵ] = ெ௘௧భିெ௘௧బூ௏஼஼భିூ௏஼஼బ  (Equation 4) 
where Met1 and Met0 are the final and initial metabolite concentrations, respectively, IVCC1 
and IVCC0 are the IVCC at final and initial time points, respectively. 
 
Transient fed-batch production of recombinant proteins 
Plasmids encoding recombinant secreted alkaline phosphatase (SEAP) and Sp35Fc fusion 
proteins were transfected into CHO-S subclones by lipofection, then cultured by FBC for 10 
days (as described above), and the recombinant protein product concentration assayed in cell-
free supernatant as previously described (Johari et al. 2015).  
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RESULTS 
CHO subclone proliferation, biomass synthesis and fed-batch culture performance 
We initially investigated whether subclonal variation in cell specific µ was related to variation 
in FBC performance. We hypothesized that increased exponential growth rate would be 
inversely proportional to late stage culture performance as CHO cell metabolism during rapid 
exponential growth is dominated by Warburg-type aerobic glycolysis (Ahn and Antoniewicz 
2013; Templeton et al. 2013; Young 2013), and increasing adaptation to this metabolic program 
to support rapid proliferation would require a proportionately large shift back to oxidative 
metabolism to support late stage culture performance. 
Each clonally-derived cell line was routinely sub-cultured using a 3-4 day split regime 
for more than 200 generations. As shown in Fig. 1, after an initial adaptation phase of 
approximately 50 generations, the mean specific growth rate increased linearly between 
generations 50 and 200, from 0.033±0.003 to 0.040±0.003 h-1 with an overall average rate of 
FKDQJHLQȝǻȝRI×10-5 h-1 generation-1 (Fig. 1, inset). 
Cell samples from all 22 clonal isolates were removed from cryopreservation at 0, 80 
and 200 generations representing early, mid and maximally evolved phases respectively, and 
FBC performance was measured after four passages post-thaw. Substantial subclone specific 
variation in culture performance with respect to viable cell concentration (VCC; Fig. 2A) and 
the integral of viable cell concentration (IVCC; Fig. 2B) were evident. As expected, the 
maximally evolved (200 generation) subclonal populations generally exhibited a significantly 
higher cumulative IVCC during the first 7 days of culture (Fig. 2C) although their subsequent 
cumulative IVCCs (post-day 7) were generally significantly below that of clonal sub-
populations evolved for shorter periods (Fig. 2D). Despite this general trend, a substantial 
clone-specific variation was maintained. For example, across all subclones the total IVCC over 
FBC varied 3-fold (from 1417 to 4207×106 cell h mL-1) and exponential ȝYDULHG-fold (from 
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0.030 to 0.041 h-1; Fig. 2E). Across all subclones, we found that increased growth rate was 
inversely correlated with cell volume (PPMCC r = –0.56, p-value < 0.001, Fig. 2E). Since it 
has been observed that CHO (and other transformed mammalian) cell biomass is directly 
proportional to cell volume (Davies et al. 2012; Dolfi et al. 2013; Frame and Hu 1990), we 
utilized both clone-specific daily VCC and cell volume measurements over the course of FBC 
(cell volume tending to decline as culture progressed; data not shown) to calculate the integral 
of viable cell mean volume (IVCV) over FBC as a simple indirect measurement of total cell 
biomass synthesis. This is analogous to measurement of packed cell volume (Stettler et al. 
2006). These data revealed that IVCV positively correlated with exponential phase ȝ (PPMCC 
r = 0.67, p-value < 0.001, not shown). Even though cells evolved for 200 generations were 
generally smaller (Fig. 2E), they were capable of higher relative biomass accumulation (IVCC 
and IVCV) during exponential phase growth, which supported generally similar IVCV 
performance over FBC (Fig. 2F). However, for the majority of subclones late stage culture 
performance was inversely proportional to increased exponential growth rates (Fig. 2C, D). 
Only 3/22 clones evolved for 200 generations (2, 4, and 17) maintained both high IVCC and 
IVCV during late stage culture. Our data reveal that for these unusual subclones, improved late 
stage FBC performance was either actually acquired during progressive subculture (subclones 
2, 17; Fig. 2D) or was stably maintained throughout (subclone 4). Other clones evolved for 
shorter periods (e.g. subclones 1, 11 at 80 generations) also exhibited relatively high late stage 
culture performance, although this was not subsequently maintained over extended subculture. 
Taken together, these data reveal that (i) the media/growth environment did not limit biomass 
accumulation during FBC for the majority of clones per se, (ii) generally, but not exclusively, 
exponential growth rate is inversely proportional to late stage culture performance, (iii) for a 
small proportion of subclones late stage culture performance can be considered a neutral trait 
with respect to the selective pressure (exponential growth rate) and is subject to variable genetic 
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drift and (iv) only a minor proportion of subclones exhibit functional stability (proliferation, 
FBC performance) over extended subculture. 
 
Optimal fed-batch culture performance is associated with elevated cellular mitochondrial 
and glycolytic capacities acquired at the onset of stationary phase culture 
In order to compare the relative ability of subclones sampled at varying stages of evolutionary 
subculture to create and maintain cellular biomass during FBC we plotted IVCC against IVCV. 
We assumed that subclones exhibiting optimal FBC performance maximize both the number 
of cellular genomes synthesized (IVCC) and the cellular biomass surrounding these genomes 
(IVCV). In the hypothetical context of a stably transfected CHO cell, this would maximize 
both the number of recombinant gene copies and cellular biomass capacity available to 
synthesize the recombinant protein product. These data, shown in Fig. 3A, reveal substantial 
(almost 4-fold) variation in FBC performance, where IVCC and IVCV are linearly related, 
which was expected as these derivative integrals are not independent. The majority of 
subclones exhibiting optimal performance according to these criteria were those that were 
maintained in subculture for 80 or 200 generations and had acquired strong late stage culture 
performance against the general evolutionary trend as previously described (identified as 
subclone.generation in subculture: 1.80, 11.80, 2.200, 4.200, 17.200). This minority of 
subclonal populations (5/66) were clearly distinct. For subsequent comparative analyses of 
metabolic function (below) we sampled three clusters of subclonal populations interspaced 
across the linear axis relating IVCC and IVCV representative of low (5 subclonal populations), 
mid (9 subclonal populations) and high (5 subclonal populations) FBC performance (indicated 
in Fig. 3A). Analysis of these groups with respect to IVCC during culture showed that although 
higher performing subclones were generally capable of more rapid exponential proliferation 
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(Fig. 3B) the majority of variation in FBC performance was a consequence of clear differences 
in the accumulation and maintenance of cell numbers during late stage culture (Fig. 3C). 
To determine whether the subclonal populations varying in FBC performance (low, 
mid, high; Fig. 3A) exhibited conserved differences in their utilization of major carbon and 
nitrogen sources (glucose, lactate, and glutamine), the cell specific flux of each metabolite was 
measured at days 3 and 7 post-inoculation, representing exponential and (onset) stationary 
phases of FBC respectively. Differences in metabolite flux normalized with respect to cell 
volume were compared (Fig. 4). These data revealed no significant heterogeneity in 
exponential phase glucose consumption and lactate production (Fig. 4A, B), where the majority 
of subclones exhibited Lac:Glu flux ratios >2 (not shown), indicating the utilization of medium 
components (e.g. amino acids) other than glucose to generate lactate. It is well known that 
rapidly proliferating cancer cells actively metabolize glutamine and other amino acids to 
pyruvate (via malic enzyme) to generate NADPH (DeBerardinis et al. 2007; Vander Heiden et 
al. 2009). However, there was a clear trend towards increased exponential phase glutamine 
consumption associated with elevated exponential growth and FBC performance (Fig. 4C). 
Across all subclonal populations stationary phase consumption of glutamine was nil (as this 
was not supplied in feeds), with no evidence of lactate resorption. However, glucose 
consumption continued (supplied in feeds), although at a relatively reduced rate (<23.4%) in 
cells exhibiting high FBC performance (Fig. 4A). 
 We hypothesized that the relative ability of cells to both proliferate rapidly and/or to 
achieve high late stage culture performance would require conserved variation in mitochondrial 
functions as this organelle is central to both biosynthetic precursor generation to support rapid 
proliferation and increased oxidative metabolism during late stage culture (Templeton et al. 
2013; Young 2013) – see also Pires das Neves et al. (2010). Accordingly, we utilized 
microplate-based measurement of oxygen consumption by live cells (Seahorse Bioscience XF 
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Analyzer) to compare the mitochondrial function of subclones at both exponential (Day 3) and 
stationary (Day 7) phases of culture. This platform technology also permits comparative 
analysis of glycolytic function by measurement of ECAR (Divakaruni et al. 2013; TeSlaa and 
Teitell 2014). These data are shown in Fig. 5 and Fig. 6. To facilitate comparative analysis we 
show mitochondrial and glycolytic functions of subclones clustered into low, medium and high 
performance rate groups as described previously (Fig. 3A). 
For each clonal derivative mitochondrial functions (basal respiration, ATP turnover, 
proton leak, maximal respiration, spare respiratory capacity, coupling efficiency and non-
mitochondrial respiration) were determined according to Brand and Nicholls (2011) by 
combining the sequential effects of optimized concentrations of oligomycin (ATP synthase 
inhibitor), FCCP (electron transport chain accelerator) and rotenone plus antimycin A (ETC 
inhibitors), and measuring the OCR after each successive addition (Fig. 5A, B for mid-
exponential and stationary growth phases respectively). Key glycolytic fluxes (basal glycolytic 
rate, glycolytic capacity, glycolytic reserve and non-glycolytic acidification) were determined 
according to TeSlaa and Teitell (2014) by combining the sequential effects of optimized 
concentrations of glucose (glycolysis induction), oligomycin (ATP synthase inhibition) and 2-
deoxy-D-glucose (glycolysis inhibition) with measurement of ECAR after each successive 
addition (Fig. 6A, B for mid-exponential and stationary growth phases respectively). 
Microplate assays were initiated in fresh XF DMEM medium containing glucose (16.74 mM) 
and glutamine (2 mM) for mitochondrial determinations or glutamine (2 mM) for glycolysis. 
To directly compare biomass-specific mitochondrial and glycolytic functions, all 
measurements were normalized using cell number and then corrected using a subclone-specific 
mean cell volume factor. 
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Mitochondrial function 
Comparative analysis of cells sampled from mid-exponential phase (Fig. 5A) and stationary 
phase (Fig. 5B) cultures revealed few conserved and significant culture phase specific 
differences in mitochondrial respiratory control. The increase in non-mitochondrial respiration 
(Fig. 5H) may be derived from an increased activity of various enzymes that consume oxygen 
(e.g. NADPH oxidases, desaturases and detoxification enzymes; (Brand and Nicholls 2011) or 
cell surface oxygen consumption via trans-plasma membrane electron transport (Herst and 
Berridge 2007) and may explain the increased basal oxygen consumption of some stationary 
phase subclones (Fig. 5C). 
In contrast, comparing subclone groups with different FBC biomass performance (Fig. 
3) and despite inherent clonal variation, we observed substantial differences in mitochondrial 
functions measured. The only (relatively small) difference in mitochondrial function evident 
for cells sampled during exponential phase culture was an increased mitochondrial coupling 
efficiency (the fraction of basal oxygen consumption used for ATP synthesis) of higher 
biomass performance cells (Fig. 5I) with a similar trend towards increased ATP turnover (Fig. 
5D). Given the absence of any differences in proton leak (Fig. 5G; a strong indicator of 
mitochondrial dysfunction), this implies that mitochondria in exponential phase higher biomass 
performance cells are capable of more efficient ATP production at similar or mildly increased 
basal respiration rates (Fig. 5C) and that this may be associated with increased growth rate 
during exponential phase culture (Fig. 2E). Moreover, these subclones were able to maintain 
mitochondrial ATP production with evidence of generally reduced spare respiratory capacity 
(Fig. 5F) without increased uncoupled maximal respiration rate (Fig. 5E). Together, we infer 
that high performance subclones may achieve high cell specific growth rate during exponential 
phase culture via higher efficiency use of available mitochondrial biomass. 
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Differences in mitochondrial respiratory control between subclone groups differing in 
FBC biomass were most evident for cells sampled from stationary phase cultures. High 
performance cells sampled from stationary phase cultures exhibited elevated basal respiration 
(oxygen consumption, Fig. 5C), ATP production (Fig. 5D), proton leak (Fig. 5G), maximal 
(uncoupled) respiration (electron transport uncoupled from mitochondrial oxygen 
consumption, Fig. 5E) and spare respiratory capacity (ability of substrate supply and electron 
transport to respond to an increase in energy demand, Fig. 5F) all normalized with respect to 
cell biomass. Importantly, these data clearly reveal a culture phase specific up-regulation of 
mitochondrial oxidative capacity specifically associated with the higher performance subclone 
groups and this is proportionate to late stage culture performance (Fig. 3C). The increase in 
proton leak (Fig. 5G) is proportionate to the increase in other mitochondrial functional 
measurements for cells sampled at stationary phase. Together these data imply that high late 
stage culture performance may be associated with increased mitochondrial biogenesis (LeBleu 
et al. 2014) and/or decreased mitochondrial protein turnover (Kitami et al. 2012) through 
culture rather than a de-repression of pre-existing mitochondrial biomass, e.g. via alleviation 
of a glucose induced inhibition of mitochondrial oxidation (the Crabtree effect; Diaz-Ruiz et 
al. (2011)), or the maintenance of a Crabtree effect in subclones exhibiting poor late stage 
culture performance. However, this is a relatively rare and possibly transient cellular 
phenotype, where subclonal evolution towards rapid exponential proliferation is, in general, 
inversely proportional to late stage culture performance (Fig. 2D).  
 
Glycolysis/ECAR 
As per mitochondrial respiratory control, comparative analysis of cells sampled from mid-
exponential phase (Fig. 6A) and stationary phase (Fig. 6B) cultures generally revealed highly 
conserved culture phase specific differences in glycolytic function. Generally, stationary phase 
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cells exhibited elevated measurements of glycolytic reserve (Fig. 6E), which is glycolytic rate 
from supplied glucose (effectively ECAR deriving from lactate production) subtracted from 
glycolytic rate after inhibition of mitochondrial ATP synthesis by oligomycin (glycolytic 
capacity, Fig. 6D). Thus, these data indicate that although glycolytic flux in exponential phase 
cells likely proceeds unconstrained at maximum capacity, a regulatory link between glycolytic 
flux to lactate and mitochondrial ATP synthesis exists in stationary phase cells generally. This 
is indicative of a fundamental alteration in metabolic programming towards a general reliance 
on oxidative metabolism as culture progresses. Secondly, the general increase in non-glycolytic 
acidification (in the unbuffered media without glucose, Fig. 6F) can derive from TCA cycle 
CO2 production (Divakaruni et al. 2013) or possibly via lactate derived from conversion of 
cytosolic malate to pyruvate, indicating significantly enhanced potential for glutamine-(or 
other amino acid) stimulated mitochondrial oxidation in stationary phase cells. 
 Comparing subclone groups with different FBC performance (Fig. 3), we observed 
clear differences in ECAR. High-performance subclones sampled at exponential phase 
exhibited relatively low glycolytic rates (Fig. 6C) and glycolytic capacities (Fig. 6D) in the 
assay medium containing glucose and glutamine (analogous to minimally conditioned medium 
during early stage culture). This contrasts markedly with the significantly higher glycolytic 
rates and capacities of the same subclones sampled during stationary phase. Moreover, high-
performance subclones sampled at stationary phase also exhibited a higher glycolytic reserve 
(Fig. 6E) and non-glycolytic ECAR (Fig. 6F). 
Taken together these observations reveal that high-performance subclones (i) are likely 
less reliant on glucose for rapid exponential phase proliferation, in accord with their higher 
glutamine uptake rate during FBC (Fig. 4C), (ii) maintain the potential for significantly higher 
glycolytic function in late stage culture relative to other cells sampled at stationary phase (Fig. 
6C-E; and also compared to their own glycolytic function when sampled during exponential 
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phase), (iii) can couple high glycolytic capacity with high mitochondrial oxidation and ATP 
synthesis capacity per unit biomass (Fig. 5), revealing a distinctly different central metabolic 
functional competency to support anabolism during late stage culture. 
However, we observed that high-performance cells exhibit reduced glucose 
consumption during late stage FBC relative to other cells with no difference in glutamine 
consumption (which was not supplied in feeds and effectively exhausted; Fig. 4). Thus, we 
infer that their inherently increased metabolic and oxidative capacity can be supported by 
increased uptake and utilization of other amino acids and/or fatty acids to support anaplerosis. 
We also note that late stage FBC medium had a high extracellular lactate concentration (up to 
30 mM) compared to that present in glycolytic and mitochondrial assays in fresh medium 
where lactic acidosis may itself prevent glycolysis (Leite et al. 2011; Mulukutla et al. 2012). 
 
Functional characterization of high-performance cells by transient production of easy-
to-express and difficult-to-express recombinant proteins 
To determine if the increased ability of high-performance subclones (1.80, 2.200, 4.200, 11.80 
and 17.200) to produce and maintain cell biomass could be harnessed to support increased 
recombinant protein production we compared production of both an “easy-to-express” (ETE) 
recombinant protein (secreted embryonic alkaline phosphatase; SEAP) and a “difficult-to-
express” (DTE) Sp35Fc fusion protein (Johari et al. 2015) in an optimized fed-batch transient 
production mode mediated by lipofection. Although the use of transient expression to compare 
clone production “capacity” has inherent limitations (e.g. variation in clone-specific 
“transfectability”, progressive dilution of plasmid copy number during cell proliferation), it 
does permit a rapid evaluation of the relative ability of cell populations to create product from 
an equivalent “load” of transfected plasmid DNA and of specific importance for a DTE protein 
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known to induce the UPR (Johari et al. 2015), the extent to which capacity for cell growth is 
inhibited by recombinant protein production. These data are shown in Fig. 7. 
 Compared to control parental cells all evolved, biomass intensive cell lines exhibited 
increased volumetric titer of SEAP after 9 days culture (from 1.19 to 1.92-fold; Fig. 7A), and 
all except clone 2.200 exhibited increased an volumetric titer of Sp35Fc (from 1.16 to 1.52-
fold; Fig. 7B). All clones except 2.200 exhibited an increased IVCC and IVCV as expected. 
However, the extent of the increase in IVCC and IVCV was more pronounced for cells 
expressing the DTE protein Sp35Fc (1.36 and 1.41-fold, respectively) than for cells expressing 
the ETE protein SEAP (1.28 and 1.32-fold, respectively). Cell specific production rates were 
clone-specific. Interestingly, subclone 1.80 attained the highest increase in product titer for 
both recombinant proteins by mostly an increase in qP (indicating a “biomass-dominant” 
phenotype) whereas subclone 17.200 which attain a very high IVCC displayed a reduced qP 
(indicating a “proliferation-dominant” phenotype). From these data, we infer that the increased 
ability of evolved cells to create and maintain cell biomass does generally support increased 
productive capacity and minimize the anti-proliferative effect of the UPR-inducing DTE 
protein Sp35Fc. Moreover, we infer that if stably transfected, evolved cells would exhibit 
greater increases in product titer as the effect of diluted plasmid copy number after transient 
transfection would be absent. 
 
DISCUSSION 
Response to the selective pressure: balancing cell biomass and exponential proliferation 
As cells increase exponential growth rate during evolutionary subculture, average CHO cell 
volume/biomass declines proportionately. This inverse relationship between cell volume and 
growth rate is typical both for CHO cells (Davies et al. 2012; Kang et al. 2014) and for other 
transformed cells in culture (Dolfi et al. 2013). The extended subculture regime we employed 
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created CHO cell lineages varying in their relationship between cell size and cell proliferation. 
Assuming a continued linear increase in specific growth rate (Fig. 1), further continuous 
subculture could have extended the phenotype towards even smaller cell size – ultimately 
towards the physical constraints imposed, for example, by correct functioning of the mitotic 
apparatus (Marshall et al. 2012). Considering all evolved cells, this evolutionary process does 
not generally yield subclonal populations that make more total cell biomass per unit time 
(IVCV), but selects for cells that presumably commit to entry into mitosis earlier in G1, 
reducing average cell size. The cell/molecular biological control mechanisms underpinning this 
change in homeostatic coupling of cell size and proliferation are not yet elucidated. Recent 
studies have established that mammalian cell division varies independently with cell size and 
age (Tzur et al. 2009), and direct observations of mammalian cell growth in microfluidic 
chambers suggest that cell growth rate varies through the cell cycle, where cells are required 
to achieve a growth rate threshold (gate) to enter into the G1-S transition (Son et al. 2012). The 
most complete mechanistic understanding of cell size control comes from studies of fission and 
budding yeasts which suggests that cells utilize a variety of sensing mechanisms to measure 
their own size and rate of biomass accumulation which regulate the timing of cell division 
(Marshall et al. 2012). Few genetic engineering strategies to increase CHO cell size and growth 
rate have been reported. Dreesen and Fussenegger (2011) employed ectopic expression of the 
metabolic sensor mTOR (mammalian target of rapamycin) to improve the capacity of 
engineered CHO cells to produce different recombinant proteins. More recently McVey et al. 
(2016) showed that knock-out of the mTORC1 inhibitor TSC2 resulted in increased cell size 
and specific production rate. Importantly however, the effects of TSC2 knockout were parental 
clone specific, and resulted in reduction of cell proliferation rate and peak cell density. 
Therefore, we utilized multiparallel evolution of subclonal populations to derive 
diverse metabolic phenotypes varying in ability to proliferate and create cellular biomass 
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during a fed-batch process. We hypothesized that evolved, rapidly proliferating smaller cells 
would acquire differences in transcriptional and metabolic programming to larger cells 
proliferating more slowly. At the most basic level, assuming cellular DNA content remains 
constant, then smaller, more rapidly dividing cells acquire a progressively higher DNA: cell 
biomass ratio, with a larger surface to volume ratio. Accordingly, we may reasonably expect 
conserved differences in global and specific transcriptional output (Marguerat and Bähler 
2012) associated with variations in total biomass synthesis rate and biomass composition. For 
example, Pires das Neves et al. (2010) showed that due the asymmetric partitioning of 
mitochondria during mitosis, HeLa cells with a higher mitochondrial mass exhibited a higher 
global transcription and proliferation rates. They proposed that elevated ATP content activates 
RNA polymerase II. More recently, an elegant study by Miettinen et al. (2014) comparing 
hepatocytes of varying size (created by decoupling growth and proliferation on ablation of 
cyclin-dependent kinase 1, such that ȝwas inversely proportional to cell size), revealed that 
the expression of mitochondrial and lipid synthesis genes was downregulated in larger cells. 
The authors associated this with a lower requirement for lipid membrane components, where 
accumulated excess lipids would inhibit lipid biosynthesis and mitochondrial metabolism. 
Thus, our hypothesis was generally correct, but with some caveats – most specifically 
concerned with the genetic stability of evolving transformed cell populations. Our data shows 
that evolutionary subculture is necessary to create CHO cell sub-populations with a markedly 
different and relatively uncommon metabolic program that supports superior FBC 
performance. However, this advantageous metabolic program arises from, and is subject to, 
genetic/functional drift; our data suggest that evolution is necessary to create new metabolic 
programs, but that these are infrequent. Most cells that acquired the ability to proliferate rapidly 
also acquired poor late stage culture performance.  
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Functional variation between and within subcultures, unsurprisingly, was pervasive. 
Genetic instability and drift within populations enabled subclones to re-program their 
metabolism and morphology to adapt to the selective pressure (Beckmann et al. 2012; Davies 
et al. 2012; Merlo et al. 2006). From an evolutionary perspective, to achieve rapid proliferation 
the genome evolves a cellular environment that can more rapidly utilize extracellular 
precursors to create the minimal amount of machinery necessary to replicate itself. This 
objective is likely achieved, in most cases, at the expense of genome fidelity, as the burden of 
genome surveillance and repair would render cells which rigorously undertook these processes 
uncompetitive within the population (Gorringe et al. 2005; Stopper et al. 2003). Hence, 
chromosomal variants and point mutations accumulate within isolated genetically drifting 
populations. Genetic and functional stability is rare. This is a hallmark of transformed cancer 
cells, which also exhibit this phenomenon (Gorringe et al. 2005). Only two of our 22 clonal 
isolates (subclones 4 and 13; Fig. 2C, D) proved functionally stable during extended subculture, 
one of which exhibited high FBC performance (subclone 4). We infer that the functional 
stability of these “antimutators” arises from their intrinsic genomic stability, which is provided 
by processes such as DNA mismatch repair during genome replication which is defective in 
many cancers (Bak et al. 2014). Arguably therefore, although subclone 1.80 exhibited superior 
manufacturing performance (Fig. 7), the functionally stable subclone 4 may be a better choice 
for a parental CHO host cell line. Whether this ideal set of properties would be carried forward 
into a new generation of stable transfectants engineered to produce recombinant proteins is an 
open question. Previous reports of “bioreactor evolved” CHO cell hosts (Prentice et al. 2007) 
would suggest that this is possible. This may be a more desirable objective phenotype as it may 
be possible to stack additional traits into an inherently stable genomic environment for more 
predictable performance characteristics. 
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Variation in metabolic phenotypes associated with exponential growth rate 
For the majority of subclones, as serial subculture progressed late stage culture performance 
declined as increased exponential growth rate increased, especially after 80 generations (Fig. 
2C, D). This inverse relationship could imply a simple progressive general limitation in 
conditioned medium sufficiency or inhibitory metabolite accumulation were it not for the group 
of high FBC performance subclones (Fig. 3A) that disprove this generality. Indeed, some 
subclones (e.g. subclones 2, 17) exhibited the opposite trend – increasing both proliferation 
and late stage culture performance during evolution. Remarkably, for subclones that did exhibit 
(albeit transiently) relatively high FBC performance, we observed highly conserved differences 
in core metabolic functions. Specifically, (i) relatively high glutamine consumption and lactate 
production during exponential growth coupled with more efficient mitochondrial oxidative 
ATP production and reduced glycolytic flux, (ii) significantly higher mitochondrial and 
glycolytic capacity available at the onset of stationary phase associated with significantly 
higher late stage culture performance. Together, these data imply that high performance CHO 
subclones utilize a distinct metabolic program that enables them to respond to the competitive 
selective pressure (growth rate) but also does not disable (or enhances) late stage culture 
performance. How can we rationalize these observations? Recent advances in knowledge of 
cancer cell metabolism may provide some insights. It is now well known that a hallmark of 
cancer cell metabolism is a reliance on glucose as a primary fuel to support aerobic glycolysis 
to lactate (Warburg 1956) and glutamine as a carbon and nitrogen source for anaplerosis and 
redox homeostasis (Hensley et al. 2013; Vander Heiden et al. 2009). The best characterized 
metabolic phenotype of tumor cells is a shift from ATP production via mitochondrial OXPHOS 
to aerobic glycolysis, where the mitochondrial TCA cycle becomes an important source of 
precursors for anabolism, such as citrate for lipid biosynthesis. PI3K/AKT1, HIF, p53, MYC 
and AMPK kinase have been implicated in metabolic re-programming of cancer cells towards 
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aerobic glycolysis which is itself an important source of precursors for anabolism via, for 
example, the oxidative pentose phosphate pathway to generate NADPH (for macromolecular 
biosynthesis and redox control) and nucleotides. In this respect allosteric regulation of the M2 
isoform of pyruvate kinase (PKM2), prevalent in transformed cells, has also been identified as 
a key effector which can, in its inactive dimeric form, shift flux of pyruvate to lactate and pool 
glycolytic intermediates to support anabolic pathways (Dong et al. 2016; Wong et al. 2013). 
Therefore, in the context of our data, the reduced exponential phase glycolytic capacity 
and increased glutamine uptake of high performance FBC cells suggest the use of a different, 
more flexible metabolic program that is characterized by conserved features. Firstly, an 
increased metabolic dependency on glutamine to support proliferation. In this case glutamine 
(via glutamate) could be utilized for anaplerosis directly, feed into the serine/glycine 
biosynthetic pathway to support protein, glutathione and nucleotide biosynthesis – a pathway 
central to cancer cell proliferation (Jain et al. 2012; Yang and Vousden 2016) and/or undergo 
reductive carboxylation by IDH1 to citrate to fuel lipid biosynthesis (Metallo et al. 2012). 
Mutational events that could support enhanced glutaminolysis have been reported. Most cited 
is the influence of MYC, which increases cell proliferation and the expression of genes that 
promote glutamine uptake and catabolism (Cairns et al. 2011; Hensley et al. 2013). More 
recently, Ma et al. (2013) have also reported that loss of PKC] expression can reprogram cancer 
cell metabolism to utilize glutamine via the serine pathway during nutrient stress. Associated 
with this mid- to high performance cells capable of increased exponential growth rate exhibited 
reduced glycolytic capacity in microplate assay conditions, where all mid- to high performance 
cells apparently operated at maximum glycolytic capacity during this phase as oligomycin (Fig. 
6D), which uncouples ATP synthesis by mitochondrial OXPHOS, did not further elevate 
ECAR. In fact, the negative glycolytic reserve derived for the majority of mid- and high-
performance cells may relate to their additional reliance on mitochondrial ATP production and 
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raises the possibility that these cells may have an additional capacity to resorb secreted lactate 
or pyruvate such that their basal “net” ECAR (Fig. 6C) is lowered. Thus, the data in Fig. 4, 
which show that actual FBC glucose consumption (Fig. 4A) measured during the same phase 
of FBC were generally equivalent can be reconciled. The increased exponential FBC lactate 
production (Fig. 4B) by high-performance cells may relate to the different culture conditions 
between microplate assay and conditioned media in FBC. We do not discount the possibility 
that a proportion of the ECAR we observed in the microplate assay conditions (Fig. 6B) may 
also be due to secretion of pyruvate itself rather than lactate, which is commonly secreted by 
cancer cells (Hong et al. 2016; Jain et al. 2012). Also, FBC may also generate lactate from 
sources other than glycolysis, for example pyruvate may be derived from malate via malic 
enzyme, where glutamine (and potentially other amino acids), which may function as an 
anaplerotic substrate in high-performance cells, is at a significantly higher concentration in 
CD-CHO medium used for FBC (8 mM) than in the medium utilized for the microplate assay 
(2 mM). Indeed, intracellular lactate has itself been shown to promote glutamine uptake by 
oxidative cancer cells (Pérez-Escuredo et al. 2016). 
It is clear that relatively high lactate production per se did not impede the exponential 
proliferation (nor subsequent late stage culture) of high-performance cells. It may be the case 
that high lactate production and export is actually advantageous for rapid proliferation not just 
as a means to recycle NAD+, but also to avoid accumulation of ROS as inactivation of LDHA 
in cancer cells has been shown to lead to ROS accumulation possibly via feedback effects on 
glycolysis (Doherty and Cleveland 2013; Le et al. 2012). Moreover, inhibition of 
monocarboxylate transporters that export lactate and pyruvate is currently under investigation 
as a promising means to block cancer cell growth (Doherty et al. 2014; Hong et al. 2016). 
Although we did not measure pyruvate concentrations, we speculate that accumulated pyruvate 
during late stage culture could be a readily available nutrient source for oxidative metabolism 
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and/or gluconeogenesis to support high-performance cells during late stage culture as 
previously described for CHO cells (Li et al. 2012; Sellick et al. 2011). Lactate consumption, 
rather than residual glucose or lactate concentrations, has been shown to be a strong indicator 
of production performance (Le et al. 2012). The fact that pH was not controlled during our 
shake-flask FBC model may also be of significance. Extracellular pH can itself affect 
metabolism; recent studies on hybridomas have shown that reduced pH (6.8) induced lactate 
import and shifted cells to a more energy efficient state with respect to ATP production, 
increasing MAb production (Ivarsson et al. 2015). Similarly, Liste-Calleja et al. (2015) shown 
that the metabolic shift to lactate consumption on HEK cells is triggered at reduced pH levels 
(6.8) as a strategy for pH detoxification. Furthermore, we speculate that the relative ability of 
cells to maintain proliferation and viability with limited external pH control may itself 
contribute to their high FBC performance. Cells utilize a variety of mechanisms to achieve 
intracellular pH homeostasis (Casey et al. 2010), and CHO cells in a metabolic culture 
environment able to exert intracellular and environmental homeostatic pH control mechanisms, 
regulating exchange of metabolites and ions to optimize maintenance of biomass may have an 
inherent advantage. For some clones it may not be necessary (and even a metabolic constraint) 
to control extracellular pH within narrow bounds. A hallmark of cancer cells is an ability to 
sense, adapt and control environmental pH (Swietach et al. 2014).  
High performance cells (as well as maximally evolved cells with high specific growth 
rate) exhibited a generally increased efficiency of mitochondrial OXPHOS during exponential 
growth. Without increasing mitochondrial capacity, ATP production is sustained by a high 
coupling efficiency (of O2 consumption to ATP production) and reduced spare OXPHOS 
capacity. Thus our data support a general conclusion that maximal growth rates are associated 
with the evolutionary acquisition of mitochondrial functional integrity to support OXPHOS 
(e.g. Fig. 3B, Fig. 5D, I), and that this is a necessary but not sufficient prerequisite for increased 
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late stage culture performance. Recent studies have also highlighted the wide diversity of 
mitochondrial functional states within tumors and between transformed cell lines (Zheng 
2012). For example, Warburg considered that dysfunctional mitochondria are required for 
aerobic glycolysis (Senyilmaz and Teleman 2015). Whilst this association may be the case in 
some cancer cells (e.g., López-Ríos et al. (2007), Owens et al. (2011)), others report intact 
mitochondrial OXPHOS in cancer cells (e.g., Fantin et al. (2006), Scott et al. (2011), Smolková 
et al. (2011)). Additionally, metabolic reliance on either glycolysis or OXPHOS can vary with 
prevailing environmental conditions. For example, OXPHOS is reported to provide 79 or 91% 
of ATP in HeLa and breast MCF cells respectively, which is reduced to 29 and 36% in hypoxia 
(Rodríguez-Enríquez et al. 2010). Aerobic glycolysis is not a universal feature of all 
proliferating cancer cells; they can exhibit considerable metabolic flexibility (Cairns et al. 
2011) in the use of amino acids, lipids or lactate as fuels (DeBerardinis et al. 2008; Sonveaux 
et al. 2008; Yang et al. 2009). Our data support the conclusion that oxidative ATP production 
by mitochondria necessarily supports both rapid proliferation and late stage culture 
performance and that continued passaging of cells may represent an indirect selection process 
for OXPHOS. Of course we expect frequent mutations in CHO mitochondrial genes occur that 
can alter mitochondrial bioenergetics and the interaction with host cell signaling pathways, 
oncogenes, metabolism (e.g. ROS formation/degradation) that regulate mitochondrial function 
(Wallace 2012). 
 
Variation in metabolic phenotypes associated with late stage culture performance 
A minority of subclonal populations acquired significantly improved late stage culture 
performance during serial subculture. Associated with this there was strong evidence of a 
substantial shift in metabolic programming when mitochondrial and glycolytic functions were 
assayed at the onset of stationary phase in the same microplate format. Importantly, the 
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unconditioned media environment of the microplate assay, albeit common across all cells, was 
distinctly different to the conditioned media environment from which the cells were sampled. 
Nevertheless, significant and conserved differences were observed, high performance cells 
exhibited both increased oxidative mitochondrial respiratory function and glycolytic activity 
(Fig. 5 and 6).These data confirm previous analyses of metabolic flux in engineered CHO cell 
lines selected for high FBC productivity which report that maximal MAb production during 
stationary phase is associated with energy generation via OXPHOS and elevated oxidative 
pentose phosphate pathway activity (Ahn and Antoniewicz 2011; Sengupta et al. 2011; 
Templeton et al. 2013). Supporting this, another flux balance analysis showed that late stage 
culture CHO cells consuming lactate have an energy efficiency (per C-mol of substrate 
consumed) six times greater than lactate producing cells (Martinez et al. 2013). 
The intricate cellular controls which enable this metabolic re-programming in some 
subclones but not others are not yet determined, but likely involve central regulators of cellular 
ATP homeostasis such as AMPK (Hardie 2014) that is known to activate mitochondrial 
biogenesis via PGC-Į, and SIRT1, a nutrient deprivation sensor that also activates PGC-Į
(Hock and Kralli 2009; Scarpulla 2011). The PGC family of coactivators (PGC-Į3GC-1ß 
and PRC) have been identified as predominant transcriptional regulators of mitochondrial 
function and biogenesis (Scarpulla 2011; Scarpulla et al. 2012) that are likely to coordinate 
synthesis of increased mitochondrial oxidative capacity in stationary phase high performance 
CHO cells. Upstream of (or in addition to) PGC coactivators, other transcription factors have 
been implicated in control of mitochondrial biogenesis and function, for example, CREB, 
MYC, OCT and YY1 (Hock and Kralli 2009; Jose et al. 2011; Scarpulla et al. 2012) which 
may all be involved in regulatory control mechanisms. Activation of mitochondrial oxidative 
capacity at stationary phase is likely to be closely associated with an energy-dependent 
regulation, since the limiting glutamine availability (glutamine levels were almost depleted at 
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stationary phase, data not shown) reduces both anaplerotic reactions and energy levels. This 
restriction can modulate the expression of PGC-1ĮYLDHLWKHU$03.(Chaube et al. 2015) or 
SIRT-1 activation (Dominy and Puigserver 2013), resulting in increased mitochondrial 
biogenesis and the OXPHOS capacity (LeBleu et al. 2014). In addition to this, cells may then 
utilize other carbon/nitrogen sources (e.g., asparagine and other branched chain amino acids) 
as anaplerotic substrates. 
The increase in glycolytic capacity we observed in stationary phase high performance 
cells is also likely to involve networks of transcription factors and signaling proteins acting in 
concert. For example, upregulation of glycolytic machinery in cancer cells is typically 
associated with downregulation of mitochondrial oxidative machinery. Oncogenic Ras 
mutations are often found in cancer cells which drive cells towards aerobic glycolysis via 
activation of the PI3K-Akt-mTOR pathway. mTOR can induce HIFs (hypoxia inducible 
transcription factors), which can induce many genes including glucose transporters and 
glycolytic enzymes (Zheng 2012). However other transcription factors such as MYC and p53 
may also play a role, where for example HIFs have been reported to both repress MYC activity 
(Zhang et al. 2007) and promote MYC transcription and cooperate with MYC in increasing 
glycolysis (Dang et al. 2008). Other layers of cellular control may also be functionally relevant. 
For example, MYC is reported to enhance mitochondrial metabolism via suppression of miR-
23a/b (Gao et al. 2009). Suppression of miR-23 activity in CHO cells has recently been reported 
to both increase mitochondrial activity and recombinant reporter protein production (Kelly et 
al. 2015). Lastly, despite evidence of metabolic reprogramming of high performance cells 
towards increased glycolytic capacity at the onset of stationary phase (Fig. 6), this was not 
actually associated with increased glucose uptake (Fig. 4). This may imply a substrate level 
control mechanism: Intracellular lactate itself may inhibit glycolysis via inhibition of 
hexokinase and phosphofructokinase (Leite et al. 2011; Mulukutla et al. 2012) thus repressing 
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the import of glucose into cells in conditioned media during FBC, but not cells in fresh, lactate-
free media in the microplate assay. Moreover, independent of glycolytic flux, an increased 
glycolytic enzyme capacity may also support a variety of non-glycolytic functions, such as 
activation of survival pathways, cell cycling and transcription etc. (Lincet and Icard 2015). 
In summary, a detailed understanding of the coordinated signaling pathways and 
oncogenes that dynamically control mitochondrial and metabolic capacity will be necessary, 
in conjunction with metabolic flux modeling, to enable not just optimization of flux to 
cell/product biomass through a generic CHO metabolic network, but optimal organization and 
capacity of the cellular network itself. We suggest that given the likely complexity and inherent 
variability of cellular control mechanisms in CHO cells (and cancer cells generally) that 
together contribute to the ideal (rapidly proliferating, biomass intensive, stable) CHO 
production phenotype, successful cell engineering strategies to achieve this objective are 
unlikely to be based on a small number of genetic alterations, even of those targets that affect 
many downstream processes (e.g. signaling nodes, transcription factors, miRNAs). If possible, 
this would likely require more sophisticated, coordinated control of the expression of multiple 
gene products simultaneously at an appropriate stoichiometry (Brown and James 2016). At 
present this multigenic cell engineering goal, to unlock the biosynthetic capacity of CHO cells, 
is more likely to be achievable via alternative strategies such as directed evolution (e.g. Prentice 
et al. (2007)) using appropriate selective environments that permit cells to achieve 
coordinated/balanced genome engineering (Birchler and Veitia 2012; Lee et al. 2014) 
underpinning the desired phenotype. In this respect, it would be possible to utilize the inherent 
genetic instability of CHO cells advantageously, balancing instability against evolutionary gain 
(Schubert and Vu 2016). 
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LIST OF FIGURES 
Fig. 1. Cell specific growth rate performance for 22 clonally-derived CHO-S cell lines 
during long-term cell culture. Clonal populations were routinely cultivated in TubeSpin 
bioreactor tubes for up to 220 generations with a 3- to 4-day subculture regime. Cell samples 
were cryopreserved at 0, 80 and 200 generations representing adaptation, mid-evolution and 
maximally evolved phases, respectively. The inset illustrates the extent of growth variability 
LQȝDQGWKHRYHUDOODYHUDJHUDWHRIFKDQJHLQȝDFURVVWKHH[WHQGHGFXOWLYDtion. The overall 
DYHUDJHUDWHRIFKDQJHLQȝZDVFDOFXODWHGDVWKHOLQHDUUHJUHVVLRQRIWKHPHGLDQYDOXHVRIWKH
observed cell growth rates at every 40 generations. Statistical significance is indicated as 
follows * P<0.05, ** P<0.01, *** P<0.001. 
 
Fig. 2. FBC performance of the 22 clonal isolates across three stages of evolutionary 
subculture. Clonal isolates were removed from cryopreservation at 0, 80 and 200 generations, 
representing adaptation, mid-evolution and maximally evolved phases, respectively. Samples 
of the FBC flasks were taken daily for VCC (A) and IVCC (B) measurements until cell viability 
dropped below 60%. The cumulative IVCV during the first 7 days of culture (C) and post-day 
7 (D) and IVCV at the end of FBC (F) of subclones.0 (dark grey bars), 80 (grey bars) and 200 
(white bars) was calculated. The insets illustrate the extent of IVCCs accumulated to Day 7 (C) 
and post-Day 7 (D) across the three evolutionary phases. Plot E shows the negative correlation 
EHWZHHQDYHUDJHFHOOYROXPHDQGȝ(PPMCC r = –0.56; p-value < 0.001). The black, grey and 
white circles represent mid-evolution and maximally evolved phases, respectively. Statistical 
significance is indicated as follows * P<0.05, ** P<0.01, *** P<0.001. 
 
Fig. 3. FBC performance of selected clones across three stages of evolutionary subculture. 
FBC performance space (A) across 66 subclonal isolates at varying evolved stages. Cumulative 
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IVCV during the first 7 days of culture (B) and their subsequent cumulative IVCCs (C) of 
selected clones (as summarized in A) with low (dark grey bars), mid (grey bars) and high (white 
bars) FBC performance. The black, grey and white circles in A represent adaptation, mid-
evolution and maximally evolved phases, respectively. The “X” represents the parental 
populations. Statistical significance is indicated as follows * P<0.05, ** P<0.01, *** P<0.001. 
 
Fig. 4. Carbon flux metabolism of selected subclonal populations varying in FBC 
performance. Cell supernatants were sampled at mid-exponential and stationary growth phase 
for the measurement of glucose, lactate and glutamine. The figures show the specific glucose 
consumption rate (A), lactate net flux (B), and glutamine consumption rate (C), respectively. 
The dark grey, grey and white bars represent subclones with low, mid, and high FBC 
performance, respectively. The bottom and top of the box represent the 25th and 75th 
percentiles, the line within the box the median, error bars indicate the 0th and 100th percentiles 
and dots are outliers. Statistical significance is indicated as follows * P<0.05, ** P<0.01, *** 
P<0.001. 
 
Fig. 5. Mitochondrial functions of selected subclonal populations varying in FBC 
performance. Cells were harvested at mid-exponential (Day 3; A) and stationary (Day 7; B) 
phase for the measurements of OCR. Triplicate measurements of the basal OCR were obtained 
in un-buffered DMEM, followed by triplicate measurements of OCR after injection of each of 
the following compounds: oligomycin, FCCP and rotenone/antimycin A. The basal 
mitochondrial respiration (C), ATP turnover (D), maximal respiration (E), spare respiratory 
capacity (F), proton leak (G), non-mitochondrial respiration (H), and coupling efficiency (I) at 
both growth phases was calculated. The dark grey, grey and white bars represent subclones 
with low, mid, and high FBC performance, respectively. The bottom and top of the box 
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represent the 25th and 75th percentiles, the line within the box the median, error bars indicate 
the 0th and 100th percentiles and dots are outliers. Statistical significance is indicated as follows 
* P<0.05, ** P<0.01, *** P<0.001. 
 
Fig. 6. Glycolytic activity of selected subclonal populations varying in FBC performance. 
Cells were harvested at mid-exponential (Day 3; A) and stationary (Day 7; B) phase for the 
measurements of their glycolytic activity. Triplicate measurements of basal ECAR were 
obtained in un-buffered DMEM, followed by triplicate measurements of ECAR after injection 
of each of the following compounds: glucose, oligomycin and 2-deoxy-glucose. The basal 
glycolytic acidification (C), glycolytic capacity (D), spare glycolytic capacity (E), and non-
glycolytic acidification (F) at both growth phases was calculated. The dark grey, grey and white 
bars represent subclones with low, mid, and high FBC performance, respectively. The bottom 
and top of the box represent the 25th and 75th percentiles, the line within the box the median, 
error bars indicate the 0th and 100th percentiles and dots are outliers. Statistical significance is 
indicated as follows * P<0.05, ** P<0.01, *** P<0.001. 
 
Fig. 7. High-performance cells exhibit increased recombinant protein production. Five 
subpopulations with superior IVCC and IVCV performance and the parental host cell line were 
HDFKWUDQVIHFWHGZLWK(?ȝJSODVPLG'1$HQFRGLQJ6($3RU6S)FXVLQJ/LSRIHFWDPLQH
LTX with PLUS reagent. Samples of the transient FBC flasks were taken daily for VCC and 
cell size measurements until cell viability dropped below 60%. SEAP and Sp35Fc titers were 
measured at day 9 post-transfection. Comparisons of manufacturing performance in terms of 
titer (black bars), IVCC (grey bars), IVCV (striped bar) and cell specific production rate (white 
bars) at day 9 for SEAP and Sp35Fc are shown in (A) and (B), respectively. Data shown are 
WKHPHDQYDOXH(?(?VWDQGDUGGHYLDWLRQRIWZRELRORJLFDODQGWZRWHFKQLFDOUHSOLFDWHV 
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